RT Journal Article
SR Electronic
T1 Resolution of <em>SLC6A1</em> variable expressivity in a multi-generational family using deep clinical phenotyping and <em>Drosophila</em> models
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.27.24314092
DO 10.1101/2024.09.27.24314092
A1 Jay, Kristy L.
A1 Gogate, Nikhita
A1 Ezell, Kim
A1 Andrews, Jonathan C.
A1 Jangam, Sharayu V.
A1 Hall, Paige I.
A1 Pan, Hongling
A1 Pham, Kelvin
A1 German, Ryan
A1 Gomez, Vanessa
A1 Jellinek-Russo, Emily
A1 Storch, Eric
A1 Brain Gene Registry Consortium
A1 Undiagnosed Diseases Network
A1 Yamamoto, Shinya
A1 Kanca, Oguz
A1 Bellen, Hugo J.
A1 Dierick, Herman
A1 Cogan, Joy D.
A1 Phillips, John A.
A1 Hamid, Rizwan
A1 Cassini, Thomas
A1 Rives, Lynette
A1 Posey, Jennifer E.
A1 Wangler, Michael F.
YR 2024
UL http://medrxiv.org/content/early/2024/09/28/2024.09.27.24314092.abstract
AB Purpose Variants in SLC6A1 result in a rare neurodevelopmental disorder characterized by a variable clinical presentation of symptoms including developmental delay, epilepsy, motor dysfunction, and autism spectrum disorder. SLC6A1 haploinsufficiency has been confirmed as the predominant pathway of SLC6A1-related neurodevelopmental disorders (NDDs), however, the molecular mechanism underlying the variable clinical presentation remains unclear.Methods Here, through work of the Undiagnosed Diseases Network, we identify an undiagnosed individual with an inherited p.(A334S) variant of uncertain significance. To resolve this case and better understand the variable expressivity with SLC6A1, we assess the phenotypes of the proband with a cohort of cases diagnosed with SLC6A1-related NDDs. We then create an allelic series in the Drosophila melanogaster to functionally characterize case variants.Results We identify significant clinical overlap between the unsolved case and confirmed cases of SLC6A1-related NDDs and find a mild to severe clinical presentation associated with missense variants. We confirm phenotypes in flies expressing SLC6A1 variants consistent with a partial loss-of-function mechanism.Conclusion We conclude that the p.(A334S) variant is a hypomorphic allele and begin to elucidate the underlying variability in SLC6A1-related NDDs. These insights will inform clinical diagnosis, prognosis, treatment and inform therapeutic design for those living with SLC6A1- related NDDs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the Vanderbilt UDN clinical site and by the UDN model organisms screening center grant U54 NS093793 to M.F.W., S.Y., H.J.B. This work was supported in part by the National Institutes of Health (NIH) Common Fund, NIH/NHGRI grant 15-HG-0130 and by the Diagnosing the Unknown for Care and Advancing Science (DUCAS) grant DUCAS-3U2CNS132415-01. This work was funded in part through support from the Potocsnak Center for Undiagnosed and Rare Disorders, and part through R01 NS107733 to MFW, also by the IDDRC-CTSA Brain Gene Registry grant, U01TR002764, from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). Brain Gene Registry participants are asked to co-enroll in GenomeConnect. GenomeConnect is supported by U24HG006834 from the NIH National Human Genome Research Institute (NHGRI). Confocal microscopy was supported in part by the Eunice Kennedy Shriver National Institute of Child Health and Human Development grant U54HD083092 to the Intellectual and Developmental Disabilities Research Center (IDDRC) Neurovisualization Core at Baylor College of Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:BCM IRB of BCM gave ethical approval for this work : H-49443I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript